FI95907C - Proteiinin merkkaus - Google Patents

Proteiinin merkkaus Download PDF

Info

Publication number
FI95907C
FI95907C FI900948A FI900948A FI95907C FI 95907 C FI95907 C FI 95907C FI 900948 A FI900948 A FI 900948A FI 900948 A FI900948 A FI 900948A FI 95907 C FI95907 C FI 95907C
Authority
FI
Finland
Prior art keywords
protein
compound
group
hydrazine
conjugate
Prior art date
Application number
FI900948A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI95907B (fi
FI900948A0 (fi
Inventor
David A Schwartz
Michael J Abrams
Christen M Giandomenico
Jon A Zubieta
Original Assignee
Johnson Matthey Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson Matthey Inc filed Critical Johnson Matthey Inc
Publication of FI900948A0 publication Critical patent/FI900948A0/fi
Application granted granted Critical
Publication of FI95907B publication Critical patent/FI95907B/fi
Publication of FI95907C publication Critical patent/FI95907C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Paints Or Removers (AREA)
  • Manufacture Of Metal Powder And Suspensions Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI900948A 1989-02-24 1990-02-23 Proteiinin merkkaus FI95907C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31527089A 1989-02-24 1989-02-24
US31527089 1989-02-24

Publications (3)

Publication Number Publication Date
FI900948A0 FI900948A0 (fi) 1990-02-23
FI95907B FI95907B (fi) 1995-12-29
FI95907C true FI95907C (fi) 1996-04-10

Family

ID=23223639

Family Applications (1)

Application Number Title Priority Date Filing Date
FI900948A FI95907C (fi) 1989-02-24 1990-02-23 Proteiinin merkkaus

Country Status (18)

Country Link
EP (1) EP0384769B1 (de)
JP (1) JP3073997B2 (de)
KR (1) KR0142079B1 (de)
AT (1) ATE137219T1 (de)
AU (1) AU630668B2 (de)
CA (1) CA2010800C (de)
DE (1) DE69026637T2 (de)
DK (1) DK0384769T3 (de)
ES (1) ES2085890T3 (de)
FI (1) FI95907C (de)
GR (1) GR3019758T3 (de)
HU (1) HU207293B (de)
IE (1) IE74849B1 (de)
IL (1) IL93432A (de)
NO (1) NO178186C (de)
NZ (2) NZ232656A (de)
PT (1) PT93264B (de)
ZA (1) ZA901283B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792444A (en) * 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
US5589576A (en) * 1989-08-29 1996-12-31 Amersham International Plc Cores for technetium radiopharmaceuticals
US6001979A (en) * 1989-08-29 1999-12-14 Nycomed Amersham Plc Cores for technetium radiopharmaceuticals
US5296599A (en) * 1991-09-19 1994-03-22 Millipore Corporation Activated carbamates compounds
GB9209641D0 (en) * 1992-05-02 1992-06-17 Johnson Matthey Plc Improvements in radiolabelling
GB9223168D0 (en) * 1992-11-05 1992-12-16 Johnson Matthey Plc Improvements in molecule labelling
US5750088A (en) * 1993-03-30 1998-05-12 The Dupont Merck Pharmaceutical Company Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
DE69408145T2 (de) * 1993-07-19 1998-09-03 Resolution Pharm Inc Hydrazine mit einer n3s konfiguration als radionukleide chelatoren
US5753206A (en) * 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
US7102024B1 (en) 2000-08-01 2006-09-05 Schwartz David A Functional biopolymer modification reagents and uses thereof
US6686461B1 (en) 2000-03-22 2004-02-03 Solulink Bioscience, Inc. Triphosphate oligonucleotide modification reagents and uses thereof
WO2001070685A2 (en) 2000-03-22 2001-09-27 Solulink, Incorporated Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
EP1877099B1 (de) 2005-04-06 2012-09-19 Genzyme Corporation Therapeutische konjugate beinhaltend ein lysosomales enzym, polysialinsäure und eine zielkomponente
DK2457920T3 (en) 2007-01-18 2018-01-22 Genzyme Corp Oligosaccharides comprising an amino oxy group and conjugates thereof
US8835614B2 (en) 2008-12-16 2014-09-16 Genzyme Corporation Oligosaccharide-protein conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57181058A (en) * 1981-04-30 1982-11-08 Ikeda Mohandou:Kk Compound labeled with 99m technetium, and its preparation
US4861869A (en) * 1986-05-29 1989-08-29 Mallinckrodt, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
DE3728599A1 (de) * 1986-12-10 1988-06-23 Hoechst Ag Verfahren zur herstellung einer mit technetium-99m-markierten organspezifischen substanz
US5066490A (en) * 1988-06-01 1991-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Protein crosslinking reagents cleavable within acidified intracellular vesicles

Also Published As

Publication number Publication date
HUT53600A (en) 1990-11-28
NO900838D0 (no) 1990-02-22
EP0384769B1 (de) 1996-04-24
DE69026637D1 (de) 1996-05-30
PT93264B (pt) 1996-01-31
ZA901283B (en) 1991-03-27
AU630668B2 (en) 1992-11-05
ATE137219T1 (de) 1996-05-15
EP0384769A2 (de) 1990-08-29
EP0384769A3 (de) 1991-11-27
JP3073997B2 (ja) 2000-08-07
HU207293B (en) 1993-03-29
GR3019758T3 (en) 1996-07-31
NZ232656A (en) 1992-04-28
IE74849B1 (en) 1997-08-13
NO178186B (no) 1995-10-30
ES2085890T3 (es) 1996-06-16
NO178186C (no) 1996-02-07
IE900666L (en) 1990-08-24
HU900970D0 (en) 1990-05-28
FI95907B (fi) 1995-12-29
KR0142079B1 (ko) 1998-06-01
NZ239288A (en) 1992-04-28
PT93264A (pt) 1990-08-31
NO900838L (no) 1990-08-27
AU5007490A (en) 1990-09-13
CA2010800A1 (en) 1990-08-24
CA2010800C (en) 2001-01-16
DK0384769T3 (da) 1996-05-13
JPH0327356A (ja) 1991-02-05
KR900012910A (ko) 1990-09-03
IL93432A (en) 1994-02-27
FI900948A0 (fi) 1990-02-23
DE69026637T2 (de) 1996-09-26

Similar Documents

Publication Publication Date Title
US6217845B1 (en) Protein labelling
FI95907C (fi) Proteiinin merkkaus
Schwartz et al. Preparation of hydrazino-modified proteins and their use for the synthesis of technetium-99m-protein conjugates
KR100346795B1 (ko) 헤테로원자-포함 리간드 및 이의 금속 착화합물
EP0420934B1 (de) Bifunktionelle kuppler und daraus hergestellte mit radionukleid markierte zusammensetzungen
FR2639947A1 (fr) Derives peptidiques
JPH02501069A (ja) トリ‐アザ大環状化合物及びそれらの金属錯体
JPH08502240A (ja) 二官能性キレート剤としての置換チオ尿素
US5094950A (en) Diethylenetriamine pentaacetic acid derivatives
JP2552714B2 (ja) ８−ヒドロキシキノリン単位からなる多座キレート化剤
JP5705434B2 (ja) キレート剤
FI113044B (fi) 2-hydratsinopyridiinijohdannaisia
EP0663900B1 (de) Metall-oxim chelate zur verwendung als röntgenpharmazeutische wirkstoffe
Banerjee et al. Design and synthesis of site directed maleimide bifunctional chelators for technetium and rhenium
US5250702A (en) Diethylenetriamine pentaacetic acid derivatives
US6660246B1 (en) Ligands and metal complexes thereof
US5858327A (en) Hydrazino-type N2 S2 radionuclide chelating compounds
Leier Chemoselective bioconjugation reactions of tyrosine residues for application in PET radiochemistry
US20070003484A1 (en) Hydroxypyridinone derivatives, metal complexes thereof and the use thereof for preparing conjugates with biomolecules
JPH03501621A (ja) チオール反応性架橋試薬

Legal Events

Date Code Title Description
BB Publication of examined application
FG Patent granted

Owner name: ANORMED INC.